To assess the extent of the Porins-induced melanoma protective T cell populations, we tested the Porins adjuvant capacity against two melanoma-associated antigens (MAA), TRP-2 and gp100, previously reported as critical antigens in cancer vaccine development (42). This evidence concerns the gene PMEL and cancer.